Wynn Resorts Q2 Reports CREATE Questions and 4 Stock Analyses To See Now

VIVUS Inc. (NASDAQ:VVUS) price target was increased by Rodman and Renshaw following the FDA’s approval of Qsymia. The firm sees the Qsymia label as positive and in-line with expectations. The firm also states that the warning language and REMS program are benign, and it maintains an Outperform rating on the stock.

Don’t Miss: Vivus VIVACIOUS! Second U.S. Diet Drug Approved in 13 Years.

Wynn Resorts Ltd.’s (NASDAQ:WYNN) Q2 results have created more questions than answers, according to the Deutsche Bank as it reduces estimates and price targets for the company. The firm reiterates a Buy rating on the stock.

EZchip Semiconductor Ltd. (NASDAQ:EZCH) estimates were reduced by Benchmark Co. before the August 8 earnings call due to weak data points for carrier spending. The firm keeps a Buy rating but lowers the price target to $45 from $49 on the stock.

Comerica Incorporated’s (NYSE:CMA) recent rally in shares of Comerica is viewed by Citigroup as a selling opportunity due to the yield curve collapse and the weak macro environment. The firm keeps a Sell rating and a $28 price target on the stock.

Royal Caribbean Cruises Ltd. (NYSE:RCL) is expected by Citigroup to confirm its annual net guidance at the lower end of the 1 percent to 4 percent range during its August 1 report of Q2 results. The firm’s channel checks suggest that trends have softened slightly since Carnival’s (NYSE:CCL) June 24 result report. The firm does think that 2013 looks good for Royal Carribean and sees a buying opportunity in any weakness in the stock after the results are reported.

Don’t Miss: Will Google SKIRT U.S. Import BAN?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.